COVID-19 Vaccination Information


ATTENTION:

There is not enough vaccine for all eligible individuals in Phases 1A and 1B to receive the COVID-19 vaccine at this time. Please check back often for updates and available appointments. The appointment schedule will be updated every Monday between 5pm and 6pm.

Are you in Phase 1A or 1B? Schedule your COVID-19 vaccinations now!

*The scheduler will be updated each Monday between 5pm - 6pm with new appointments.

CHOOSE YOUR LOCATION:

BRING THIS FORM WITH YOU TO YOUR APPOINTMENT. Do not mail or fax this form in to GCHD.

*Download a PDF version with links, here .
COVID-19 Vaccination Prioritization Guide (MDHHS)

Considerations Prior to COVID-19 Vaccinations


Pfizer-BioNTech Vaccine :

  • Approved for ages 16+
  • Two-doses, 21 days apart

Moderna Vaccine :

  • Approved for ages 18+
  • Two-doses, 28 days apart

Co-administration with other vaccines :

  • The COVID-19 series should be administered alone
  • The COVID-19 vaccine should be administered a minimum of 14 days before or after other vaccinations

Persons with current or prior history of COVID-19 infection :

  • Trials indicate the mRNA COVID-19 vaccines are safe for persons with evidence of a prior COVID-19 infection
  • Vaccinations should be offered regardless of history of prior symptomatic or asymptomatic infection
  • Vaccination of persons with current COVID-19 infection should be deferred until recovery from the acute illness and criteria have been met to discontinue isolation

Persons with a known COVID-19 exposure should not seek vaccination until their quarantine period has ended

  • Residents with a known COVID-19 exposure living in congregate healthcare settings (e.g., long-term care facilities), where exposure and transmission of SARS-CoV-2 can occur repeatedly for long periods of time, may be vaccinated
  • Residents of other congregate settings (e.g., correctional and detention facilities, homeless shelters) with a known COVID-19 exposure may also be vaccinated

Persons who previously received passive antibody therapy :

  • Based on current evidence, reinfection is uncommon in the 90 days after initial infection
  • Vaccination should be deferred for at least 90 days as a precautionary measure

Observation Period :

  • The CDC recommends 15 minute observation period following COVID-19 vaccinations
  • For those with a history of anaphylaxis, a 30 minute observation period is recommended

Vaccination during Pregnancy & Lactation :

  • COVID-19 mRNA vaccinations were not tested on pregnant or lactating persons; there is no safety data available for these groups
  • A lactating person who is part of a group recommended to receive a COVID-19 vaccine (e.g., healthcare personnel) may choose to be vaccinated
  • If pregnant people are part of a group that is recommended to receive a COVID-19 vaccine (e.g., healthcare personnel), they may choose to be vaccinated.
  • A conversation between the patient and their clinical team may assist with decisions regarding the use of a mRNA COVID-19 vaccine, though a conversation with a healthcare provider is not required prior to vaccination
  • When making a decision, pregnant people and their healthcare providers should consider:
    • The level of COVID-19 community transmission
    • The patient’s personal risk of contracting COVID-19,
    • The risks of COVID-19 to the patient and potential risks to the fetus,
    • The efficacy of the vaccine,
    • The side effects of the vaccine, and
    • The lack of data about the vaccine during pregnancy

Allergic Reactions :

  • COVID-19 vaccinations contain no latex, egg , or gelatin: persons with allergies to these items can receive the COVID-19 mRNA vaccinations without concern
  • Allergic reactions not related to vaccines, injectable therapies, components of mRNA COVID-19 vaccines (including PEG), or polysorbates, such as food, pet, venom, or environmental allergies, or allergies to oral medications are NOT contraindications to vaccination with mRNA COVID-19 vaccines

V-Safe Application :

  • Voluntary smartphone based tool
  • Uses text messages and web surveys to provide real-time health check-ins after persons receive COVID-19 vaccinations
  • Reports of adverse reactions may be followed up by CDC/V-Safe call centers to collect additional information if applicable

General Vaccine Information


Vaccine Development — 101 | El desarrollo de las vacunas – 101

How mRNA Vaccines Work (MDHHS)

COVID-19 Vaccinations in Michigan


COVID-19 Vaccine FAQs (MDHHS)

Protecting Michigan’s Critical Infrastructure: Vaccination Phases 1B + 1C (MDHHS)

Michigan COVID-19 Vaccination Dashboard

COVID-19 Vaccine Information for Consumers


COVID 19 Vaccine Deep Dive: Safety, Immunity, RNA Production
FDA Emergency Use Authorization
How Vaccines are Developed
Pfizer BioNTech COVID Vaccine (Clinical Considerations)
COVID-19 Vaccination Recommendations
Operation Warp Speed

Ensuring Vaccine Safety

How CDC is Making Vaccination Recommendations: Who Gets Vaccinated First?

Benefits of Vaccination

Information on the Pfizer-BioNTech Vaccine

NIH: Understanding Clinical Trials

COVID-19 Vaccine Information for Providers


Education + Information for Providers (MDHHS)

Healthcare Professionals: Preparing for COVID-19 Vaccination (CDC)

Vaccine Storage + Handling Toolkit (CDC)

Pharmacy Partnership for LTC Vaccinations (CDC)

Importance of COVID-19 Vaccination for LTC Residents (CDC)

Post Vaccine Consideration for LTC Residents (CDC)

Vaccinations for Healthcare Offices


We anticipate notification that COVID-19 vaccinations will be available in the coming weeks. Please complete the attached FORM and return it to the email address on the form. We will contact you when you can be immunized.